Cargando…

Comparison of the Immune Responses to Different Formulations of BC02-Adjuvanted HPV Types 16 and 18 Bivalent Vaccines in Mice

To achieve maximum efficacy, vaccines, such as subunit, recombinant, and conjugate vaccines, necessitate the incorporation of immunostimulators/adjuvants. Adjuvants play a vital role in bolstering and extending the strength of the immune response while also influencing its type. As antigen and adjuv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junli, Xie, Huicong, Fu, Lili, Guo, Xiaonan, Dong, Jiaxin, Xu, Miao, Wang, Guozhi, Zhao, Aihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611034/ https://www.ncbi.nlm.nih.gov/pubmed/37896956 http://dx.doi.org/10.3390/vaccines11101553

Ejemplares similares

Novel BC02 Compound Adjuvant Enhances Adaptive and Innate Immunity Induced by Recombinant Glycoprotein E of Varicella-Zoster Virus
por: Li, Junli, et al.
Publicado: (2022)

Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant
por: Li, Junli, et al.
Publicado: (2022)

The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs
por: Guo, Xiaonan, et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
por: Kavanagh, K, et al.
Publicado: (2014)

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study
por: Mesher, David, et al.
Publicado: (2016)

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
por: Kreimer, Aimée R., et al.
Publicado: (2011)

Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
por: Yao, Xingmei, et al.
Publicado: (2022)

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens
por: Arribillaga, Laura, et al.
Publicado: (2020)

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
por: Wacholder, Sholom, et al.
Publicado: (2010)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
por: Kumakech, Edward, et al.
Publicado: (2016)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia
por: Mu, Lin, et al.
Publicado: (2020)

Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems
por: Lin, Chih-Wei, et al.
Publicado: (2014)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Therapeutic Effect of Subunit Vaccine AEC/BC02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model
por: Lu, Jinbiao, et al.
Publicado: (2022)

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
por: Harper, Diane M., et al.
Publicado: (2011)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
por: Chua, Brandon Wen Bing, et al.
Publicado: (2022)

HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation
por: Yu, Lulu, et al.
Publicado: (2022)

Unmethylated CpG motif-containing genomic DNA fragment of Bacillus calmette-guerin promotes macrophage functions through TLR9-mediated activation of NF-κB and MAPKs signaling pathways
por: Li, Junli, et al.
Publicado: (2019)

Adjuvant action of needle-shaped BC microfibrils
por: Süer, Özge, et al.
Publicado: (2023)

Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data
por: Huygen, Frank, et al.
Publicado: (2015)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Absence of HPV 16 and 18 DNA in breast cancer.
por: Wrede, D., et al.
Publicado: (1992)

Monitoring HPV16/18 immunisation in England and elsewhere
por: Franceschi, S
Publicado: (2010)

Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
por: Arbyn, Marc, et al.
Publicado: (2020)

Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy
por: Hammad, Noha M., et al.
Publicado: (2021)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Rapid detection of high-risk HPV16 and HPV18 based on microchip electrophoresis
por: Fan, Zhaoxuan, et al.
Publicado: (2020)

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
por: Jimeno, Antonio, et al.
Publicado: (2023)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
por: Hu, Shangying, et al.
Publicado: (2020)

Assessment of HPV 16, HPV 18, p16 expression in advanced stage laryngeal cancer patients and prognostic significance()()
por: Dogantemur, Selman, et al.
Publicado: (2019)

Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant
por: Ruiz, Wanda, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_cf0mppa5srg5h0adobn2shsn1o